No insider purchase over the last 90 days. The latest was filed 17 Mar 2026.
Shoulder Innovations, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 43 filings came from 13 insiders.
Purchases and sales both appear in the filings: 4 purchases (3 insiders, €96k) and 17 sales (3 insiders, €4.4M). The amount is not disclosed for 3 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 1 finance chief, 1 senior executive and 1 chief executive. Gilde Healthcare Holding B.V. filed the largest sale, €2.0M, on 5 August 2026, which represents 0.63% of the company's market value.
Compared with its exchange (250 companies, median 4 filings), a count of 43 filings is above the norm. The full history, which starts in 2025, counts 6 purchases against 17 sales.
The data flag 4 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The clock since the last published purchase (17 March 2026) now reads 215 days. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2025 · cache
25 of 59 declarations
Shoulder Innovations, Inc. is a company focused on developing medical solutions for shoulder injuries. It emphasizes innovation and improvement in surgical treatments.